Logo image of NSTG

NANOSTRING TECHNOLOGIES INC (NSTG) Stock Fundamental Analysis

NASDAQ:NSTG - Nasdaq - US63009R1095 - Common Stock - Currency: USD

0.1053  -0.06 (-37.43%)

After market: 0.1051 0 (-0.19%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to NSTG. NSTG was compared to 56 industry peers in the Life Sciences Tools & Services industry. NSTG has a bad profitability rating. Also its financial health evaluation is rather negative. NSTG is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year NSTG has reported negative net income.
NSTG had a negative operating cash flow in the past year.
NSTG had negative earnings in each of the past 5 years.
NSTG had a negative operating cash flow in each of the past 5 years.
NSTG Yearly Net Income VS EBIT VS OCF VS FCFNSTG Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 -50M -100M -150M

1.2 Ratios

NSTG has a worse Return On Assets (-60.59%) than 91.80% of its industry peers.
Industry RankSector Rank
ROA -60.59%
ROE N/A
ROIC N/A
ROA(3y)-29.8%
ROA(5y)-31.5%
ROE(3y)-149.76%
ROE(5y)-139.62%
ROIC(3y)N/A
ROIC(5y)N/A
NSTG Yearly ROA, ROE, ROICNSTG Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 -100 -200 -300

1.3 Margins

NSTG's Gross Margin of 35.72% is on the low side compared to the rest of the industry. NSTG is outperformed by 62.30% of its industry peers.
NSTG's Gross Margin has declined in the last couple of years.
NSTG does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 35.72%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-9.22%
GM growth 5Y-7.64%
NSTG Yearly Profit, Operating, Gross MarginsNSTG Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 0 50 -50 -100

More info and screens

2

2. Health

2.1 Basic Checks

NSTG does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for NSTG has been increased compared to 1 year ago.
The debt/assets ratio for NSTG is higher compared to a year ago.
NSTG Yearly Shares OutstandingNSTG Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M 40M
NSTG Yearly Total Debt VS Total AssetsNSTG Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 100M 200M 300M 400M 500M

2.2 Solvency

Based on the Altman-Z score of -5.51, we must say that NSTG is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -5.51, NSTG is doing worse than 81.97% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -5.51
ROIC/WACCN/A
WACC2.41%
NSTG Yearly LT Debt VS Equity VS FCFNSTG Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 100M -100M 200M 300M

2.3 Liquidity

A Current Ratio of 2.73 indicates that NSTG has no problem at all paying its short term obligations.
NSTG has a Current ratio of 2.73. This is comparable to the rest of the industry: NSTG outperforms 52.46% of its industry peers.
A Quick Ratio of 2.02 indicates that NSTG has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 2.02, NSTG is in line with its industry, outperforming 47.54% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.73
Quick Ratio 2.02
NSTG Yearly Current Assets VS Current LiabilitesNSTG Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 100M 200M 300M 400M

More info and screens

5

3. Growth

3.1 Past

NSTG shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -12.42%.
NSTG shows a strong growth in Revenue. In the last year, the Revenue has grown by 20.09%.
NSTG shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 2.07% yearly.
EPS 1Y (TTM)-12.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%1.27%
Revenue 1Y (TTM)20.09%
Revenue growth 3Y0.45%
Revenue growth 5Y2.07%
Sales Q2Q%62.8%

3.2 Future

Based on estimates for the next years, NSTG will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.87% on average per year.
The Revenue is expected to grow by 22.47% on average over the next years. This is a very strong growth
EPS Next Y4.9%
EPS Next 2Y22.45%
EPS Next 3Y18.14%
EPS Next 5Y15.87%
Revenue Next Year40.02%
Revenue Next 2Y26.22%
Revenue Next 3Y23.31%
Revenue Next 5Y22.47%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
NSTG Yearly Revenue VS EstimatesNSTG Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 100M 200M 300M 400M 500M
NSTG Yearly EPS VS EstimatesNSTG Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 -1 -2 -3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for NSTG. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NSTG. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NSTG Price Earnings VS Forward Price EarningsNSTG Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NSTG Per share dataNSTG EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2

4.3 Compensation for Growth

NSTG's earnings are expected to grow with 18.14% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y22.45%
EPS Next 3Y18.14%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for NSTG!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NANOSTRING TECHNOLOGIES INC

NASDAQ:NSTG (2/13/2024, 9:56:56 PM)

After market: 0.1051 0 (-0.19%)

0.1053

-0.06 (-37.43%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)11-06 2023-11-06/amc
Earnings (Next)02-27 2024-02-27/amc
Inst Owners0%
Inst Owner Change-97.01%
Ins Owners17.53%
Ins Owner Change0%
Market Cap5.07M
Analysts76.92
Price Target2.07 (1865.81%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-32.73%
Min EPS beat(2)-33.62%
Max EPS beat(2)-31.85%
EPS beat(4)0
Avg EPS beat(4)-36.24%
Min EPS beat(4)-61.05%
Max EPS beat(4)-18.46%
EPS beat(8)0
Avg EPS beat(8)-33.39%
EPS beat(12)0
Avg EPS beat(12)-25.98%
EPS beat(16)1
Avg EPS beat(16)-25.37%
Revenue beat(2)1
Avg Revenue beat(2)0.84%
Min Revenue beat(2)-0.12%
Max Revenue beat(2)1.8%
Revenue beat(4)3
Avg Revenue beat(4)1.93%
Min Revenue beat(4)-0.12%
Max Revenue beat(4)5.95%
Revenue beat(8)4
Avg Revenue beat(8)-2.76%
Revenue beat(12)7
Avg Revenue beat(12)-1.56%
Revenue beat(16)11
Avg Revenue beat(16)2.19%
PT rev (1m)0%
PT rev (3m)-78.95%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-19.5%
EPS NY rev (1m)0%
EPS NY rev (3m)-13.5%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-4.25%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-2.27%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.03
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-3.53
EYN/A
EPS(NY)-1.73
Fwd EYN/A
FCF(TTM)-2.82
FCFYN/A
OCF(TTM)-2.39
OCFYN/A
SpS3.38
BVpS-1.05
TBVpS-1.05
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -60.59%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 35.72%
FCFM N/A
ROA(3y)-29.8%
ROA(5y)-31.5%
ROE(3y)-149.76%
ROE(5y)-139.62%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-9.22%
GM growth 5Y-7.64%
F-Score2
Asset Turnover0.59
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 144.24%
Cap/Sales 12.78%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.73
Quick Ratio 2.02
Altman-Z -5.51
F-Score2
WACC2.41%
ROIC/WACCN/A
Cap/Depr(3y)187.15%
Cap/Depr(5y)166.43%
Cap/Sales(3y)10.15%
Cap/Sales(5y)8.19%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-12.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%1.27%
EPS Next Y4.9%
EPS Next 2Y22.45%
EPS Next 3Y18.14%
EPS Next 5Y15.87%
Revenue 1Y (TTM)20.09%
Revenue growth 3Y0.45%
Revenue growth 5Y2.07%
Sales Q2Q%62.8%
Revenue Next Year40.02%
Revenue Next 2Y26.22%
Revenue Next 3Y23.31%
Revenue Next 5Y22.47%
EBIT growth 1Y-18.81%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year34.66%
EBIT Next 3Y23.81%
EBIT Next 5Y19.06%
FCF growth 1Y-50.97%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-37.03%
OCF growth 3YN/A
OCF growth 5YN/A